Products
| Discovery & POC | Lead Optimization | Assets | Pre-clinical | GMP | Clinical Study | Collaborations |
|---|
KISIMA®
| Discovery & POC | Lead Optimization | Assets | Pre-clinical | GMP | Clinical Study | Collaborations |
|---|
Our therapeutic vaccines programmes
ATP128
Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of colorectal cancer.
Colorectal cancer is a leading cause of mortality and provides a significant market opportunity ($11 billion by 2025) for us with few cancer vaccine competitors.
This target is well suited for the self-adjuvanting KISIMA® immunisation platform which is able to turn a cold tumour into a hot tumour in this programme, promoting the tumour infiltration by immune cells.
ATP128 is expected to enter phase I clinical trials in 2019.
Other programmes
Our other therapeutic vaccine programmes include one oncology programme in pre-clinical stage. AMAL also plans to expand its development to infectious diseases.
Amal Therapeutics SA
c/o Fondation pour Recherches Médicales
64 av. de la Roseraie
1205 Geneva
Switzerland
